TGF-β/Smad Signaling


The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
-
B5946 EW-71971 CitationTarget: BMP and Other Activin ReceptorsSummary: Selective inhibitor of TGF-β type I receptor kinase -
B5954 Dasatinib MonohydrateTarget: PDGFR|c-Kit|Bcr-Abl|SrcSummary: Inhibitor of ABL, SRC, KIT, PDGFR, and other tyrosine kinases. -
N1357 Asiaticoside1 Citation -
N1567 DaphnetinSummary: Protein kinases inhibitor for EGFR/PKA/PKC -
N1835 Oxymatrine -
N2739 Hypericin -
N2660 Alantolactone -
A8830 ZIP (SCRAMBLED)Summary: PKMζ inhibitor -
B3447 ValrubicinSummary: chemotherapy drug used to treat bladder cancer -
B3687 LDN-212854Summary: BMP receptor inhibitor,potent and selective

